131786-48-6 Usage
General Description
5-METHYL-2-(3-PYRIDINYL)-1,3-THIAZOL-4-OL, also known as rufinamide, is an antiepileptic drug used to treat seizures associated with Lennox-Gastaut syndrome. It works by regulating the activity of sodium channels in the brain, which helps to prevent abnormal electrical activity that can lead to seizures. Rufinamide is a thiazole derivative and acts as a selective modulator of the voltage-gated sodium channel. It is typically taken orally in the form of tablets or oral suspension and has been found to be effective in reducing the frequency and severity of seizures in people with Lennox-Gastaut syndrome. Common side effects of rufinamide include dizziness, fatigue, and nausea. It is important to take rufinamide as prescribed by a healthcare professional to minimize the risk of side effects and optimize its effectiveness in controlling seizures.
Check Digit Verification of cas no
The CAS Registry Mumber 131786-48-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,7,8 and 6 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 131786-48:
(8*1)+(7*3)+(6*1)+(5*7)+(4*8)+(3*6)+(2*4)+(1*8)=136
136 % 10 = 6
So 131786-48-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2OS/c1-6-8(12)11-9(13-6)7-3-2-4-10-5-7/h2-5,12H,1H3
131786-48-6Relevant articles and documents
BENZOXAZINE DERIVATIVES AS CRAC MODULATORS
-
Paragraph 0150, (2013/04/13)
Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).
DIAZAINDOLE INHIBITORS OF CRAC
-
Paragraph 0108, (2013/06/28)
Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
4-AZAINDOLE INHIBITORS OF CRAC
-
Paragraph 0106, (2013/06/28)
Disclosed are compounds of Formula (I): useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.